

Editorial

Using Stereotactic Body Radiation Therapy (SBRT) to Irradiate and Re-Irradiate Prostate Cancer

Rex Cheung*

Flushing Radiation Oncology CyberKnife Center, USA

***Corresponding author:** Rex Cheung, MD, PhD,
Flushing Radiation Oncology CyberKnife Center, 40-20
Main Street, 4th Floor, Flushing, NY 11354, USA

Received: September 17, 2014; **Accepted:** December 02, 2014; **Published:** December 04, 2014

Keywords

Prostate cancer; Recurrent prostate cancer; Re-Irradiation; Stereotactic radiotherapy; CyberKnife

Background

Prostate cancer is the leading cause of invasive cancer of men in the U.S according to 2010 Surveillance, Epidemiology and End Results (SEER) data [1] compiled by Center for Disease Control and Prevention (CDC). The annual rate of prostate cancer diagnosis was 126.1 per 100,000 men in 2010 [1]. Prostate Specific Antigen (PSA) and digital rectal examination screening have attributed to improved detection and treatment outcome of prostate cancer [2,3]. The freedom from biochemical or clinical relapse is about 22 % at 8.7 years with 78 Gy radiation treatment alone [4]. There is still room for improvement in treatment outcome [5]. Androgen deprivation with radiation treatment has improved prostate cancer treatment outcome [6] but is associated with significant toxicities [7]. Radiation dose escalation has been hampered by the possibility of increased treatment toxicities. This paper discusses the use of stereotactic radiotherapy as a means of increasing the dose of prostate radiotherapy while minimizing treatment toxicities. This is a part of a series describes utilizing advanced radiation treatment systems in challenging clinical scenarios [8].

Stereotactic radiation treatment of prostate cancer

With prostate cancer α/β ratio is estimated to be between 1.5 – 3 [9,10], hypofractionated stereotactic body radiation treatment (SBRT) delivers more biologic effective dose (BED) [11] to the prostate cancer. Some investigators have argued using high dose rate (HDR) may be better than SBRT in tumor coverage and organ sparing [12]. But SBRT may be a more convenient radiation treatment.

Radiation dose escalation has produced improved prostate cancer radiation treatment outcome [4,13]. But attention to rectal [14] and bladder [15] doses is needed to prevent increased treatment toxicities. Prostate interfraction [16,17] and intrafraction [18] organ motion have limited decreasing the treatment margin to further spare critical organs at risk including rectum, bladder and penile base. On MRI, the levatorani is concave at the prostatic apex, and convex below the apex [19]. This may help to contour the penile bulb to spare the penile base [20]. With full bladder, empty rectum, 3 mm margin may be enough

[21] to treat the prostate alone. With fiducials tracking, stereotactic radiation systems could achieve a safe posterior margin of about 2 mm and 5 mm in other directions to spare normal tissues [22]. Prostate cancer patients treated with SBRT have been found to have good quality of life after radiation treatment [22-25]. Alpha-agonist use could rise 40% 18 months after SBRT, but grade 3 urinary toxicity is low, about 1-2% [26]. Sexual potency is comparable to conventional radiation modalities [27].

SBRT of prostate cancer with CyberKnife produces good dose fall off as Intensity Modulated Radiation Treatment (IMRT) using a large number of beams [28]. However, SBRT may be more cost effective than IMRT [29]. With fiducials placement CyberKnife can track organ motion. SBRT of prostate cancer could be done with linac based machines for example Varian Trilogy with on-board imaging and IMRT capacities [30], and other advance stereotactic radiation systems [31].

SBRT of prostate cancer is an effective radiation treatment for organ confined prostate cancer [32]. However, competing technologies SBRT, hypofractionation, proton therapy [33] and HDR [34] should be studied for cost effectiveness [35,36]. Furthermore, novel systemic treatment may be combined with radiation treatment in the future to improve treatment outcome [37]. However, this should proceed cautiously when large fraction size of SBRT is considered [38].

Re-irradiation of prostate cancer

Radio-resistant recurrent prostate cancer has been treated with external beam [39] and with brachytherapy [40]. SBRT has also been used in treating recurrent prostate cancer [41], lymphadenopathy and bone metastasis [42]. In one study, six recurrent prostate cancer patients after external beam radiotherapy were treated to 30 Gy in 5 fractions [41]. No prostatic progression was found, and no major rectal or urinary toxicity were found with a median follow up of 11.2 months [41]. In another study, CyberKnife was used in re-irradiating recurrent lateral pelvic malignancies [43]. With a dose of 36 Gy in six fractions over 3 weeks, the median dose of prior treatment was 45 Gy (Biologic Equivalent Dose at 2 Gy (EQD2) [44] range: 20 – 96 Gy [43]). The median size of the tumor target was 34.5 mm [43]. Median disease free interval from initial treatment to recurrence was 27 months (range 4 - 148 months). Actuarial local control rate was 51.4% at one year. There were no major toxicities [43].

Conclusion

SBRT may be a safe and effective in irradiating and re-irradiating prostate cancer with advanced radiation therapy systems [45-47].

Reference

1. Henley SJ, Singh S, King J, Wilson R, Ryerson B. Invasive cancer incidence - United States, 2010. *MMWR Morb Mortal Wkly Rep.* 2014; 63: 253-259.
2. Nogueira L, Corradi R, Eastham JA. Prostatic specific antigen for prostate

- cancer detection. *Int Braz J Urol.* 2009; 35: 521-529.
3. Pashtan I, Chen MH, D'Amico AV. The impact of PSA and digital rectal examination on the risk of prostate cancer specific mortality in men with a PSA level <2.5ng/ml. *Cancer Epidemiol.* 2014; 38: 613-618.
 4. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. *Int J Radiat Oncol Biol Phys.* 2008; 70: 67-74.
 5. Cheung MR. The need and prospect of individualized external beam radiotherapy dose escalation beyond 80 Gy to treat prostate cancer: in regard to Eade et al. (*Int J Radiat Oncol Biol Phys.* 2007; 68: 682-689). *Int J Radiat Oncol Biol Phys.* 2008; 70: 645-646.
 6. Bolla M, Verry C, Long JA. High-risk prostate cancer: combination of high-dose, high-precision radiotherapy and androgen deprivation therapy. *Curr Opin Urol.* 2013; 23: 349-354.
 7. Edelman S, Butler J, Hershatter BW, Khan MK. The Effects of Androgen Deprivation Therapy on Cardiac Function and Heart Failure: Implications for Management of Prostate Cancer. *Clin Genitourin Cancer.* 2014.
 8. Cheung R. Using a Robotic Stereotactic Radiation Treatment System to Treat Benign Intracranial Tumors and Trigeminal Neuralgia. *Austin J Radiat Oncol & Cancer.* 2014; 1: 2.
 9. Sudahar H, Kurup PG, Murali V, Mahadev P, Velmurugan J. Equivalent normalized total dose estimates in cyberknife radiotherapy dose delivery in prostate cancer hypofractionation regimens. *J Med Phys.* 2012; 37: 90-96.
 10. Townsend NC, Huth BJ, Ding W, Garber B, Mooreville M, Arrigo S, et al. Acute toxicity after cyberknife-delivered hypofractionated radiotherapy for treatment of prostate cancer. *Am J Clin Oncol.* 2011; 34: 6-10.
 11. Fowler JF. 21 years of biologically effective dose. *Br J Radiol.* 2010; 83: 554-568.
 12. Sudahar H, Kurup PG, Murali V, Mahadev P, Velmurugan J. Analysis of high-dose rate brachytherapy dose distribution resemblance in CyberKnife hypofractionated treatment plans of localized prostate cancer. *Med Dosim.* 2013; 38: 385-389.
 13. Kuban DA, Levy LB, Cheung MR, Lee AK, Choi S, Frank S, et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? *Int J Radiat Oncol Biol Phys.* 2011; 79: 1310-1317.
 14. Tucker SL, Dong L, Bosch WR, Michalski J, Winter K, Mohan R, et al. Late rectal toxicity on RTOG 94-06: analysis using a mixture Lyman model. *Int J Radiat Oncol Biol Phys.* 2010; 78: 1253-1260.
 15. Cheung MR, Tucker SL, Dong L, de Crevoisier R, Lee AK, Frank S, et al. Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer. *Int J Radiat Oncol Biol Phys.* 2007; 67: 1059-1065.
 16. de Crevoisier R, Melancon AD, Kuban DA, Lee AK, Cheung RM, Tucker SL, et al. Changes in the pelvic anatomy after an IMRT treatment fraction of prostate cancer. *Int J Radiat Oncol Biol Phys.* 2007; 68: 1529-1536.
 17. Frank SJ, Dong L, Kudchadker RJ, De Crevoisier R, Lee AK, Cheung R, et al. Quantification of prostate and seminal vesicle interfraction variation during IMRT. *Int J Radiat Oncol Biol Phys.* 2008; 71: 813-820.
 18. van de Water S, Valli L, Aluwini S, Lanconelli N, Heijmen B, Hoogeman M, et al. Intrafraction prostate translations and rotations during hypofractionated robotic radiation surgery: dosimetric impact of correction strategies and margins. *Int J Radiat Oncol Biol Phys.* 2014; 88: 1154-1160.
 19. McLaughlin PW, Narayana V, Meirovitz A, Troyer S, Roberson PL, Gonda R Jr, et al. Vessel-sparing prostate radiotherapy: dose limitation to critical erectile vascular structures (internal pudendal artery and corpus cavernosum) defined by MRI. *Int J Radiat Oncol Biol Phys.* 2005; 61: 20-31.
 20. Magli A, Giangreco M, Crespi M, Negri A, Ceschia T, De Giorgi G, et al. Erectile dysfunction after prostate three-dimensional conformal radiation therapy. Correlation with the dose to the penile bulb. *Strahlenther Onkol.* 2012; 188: 997-1002.
 21. Melancon AD, O'Daniel JC, Zhang L, Kudchadker RJ, Kuban DA, Lee AK, et al. Is a 3-mm intrafractional margin sufficient for daily image-guided intensity-modulated radiation therapy of prostate cancer? *Radiat Oncol.* 2007; 85: 251-259.
 22. Koh DH, Kim JB, Kim HW, Chang YS, Kim HJ. Clinical Outcomes of CyberKnife Radiotherapy in Prostate Cancer Patients: Short-term, Single-Center Experience. *Korean J Urol.* 2014; 55: 172-177.
 23. King CR, Collins S, Fuller D, Wang PC, Kupelian P, Steinberg M, et al. Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. *Int J Radiat Oncol Biol Phys.* 2013; 87: 939-945.
 24. King CR, Brooks JD, Gill H, Presti JC Jr. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. *Int J Radiat Oncol Biol Phys.* 2012; 82: 877-882.
 25. Katz AJ, Santoro M, Ashley R, Diblasio F. Stereotactic Body Radiation Therapy for Low- and Low-Intermediate-Risk Prostate Cancer: Is there a Dose Effect? *Front Oncol.* 2011; 1: 49.
 26. Arscott WT, Chen LN, Wilson N, Bhagat A, Kim JS, Moures RA, et al. Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer. *Radiat Oncol.* 2014; 9: 163.
 27. Obayomi-Davies O, Chen LN, Bhagat A, Wright HC, Uhm S, Kim JS, et al. Potency preservation following stereotactic body radiation therapy for prostate cancer. *Radiat Oncol.* 2013; 8: 256.
 28. Hossain S, Xia P, Huang K, Descovich M, Chuang C, Gottschalk AR, et al. Dose gradient near target-normal structure interface for nonisocentric CyberKnife and isocentric intensity-modulated body radiotherapy for prostate cancer. *Int J Radiat Oncol Biol Phys.* 2010; 78: 58-63.
 29. Sher DJ, Parikh RB, Mays-Jackson S, Punglia RS. Cost-effectiveness Analysis of SBRT Versus IMRT for Low-risk Prostate Cancer. *Am J Clin Oncol.* 2014; 37: 215-221.
 30. Pawlicki T, Kim GY, Hsu A, Cotrutz C, Boyer AL, Xing L, et al. Investigation of linac-based image-guided hypofractionated prostate radiotherapy. *Med Dosim.* 2007; 32: 71-79.
 31. Sterzing F, Schubert K, Sroka-Perez G, Kalz J, Debus J, and Herfarth K. Helical tomotherapy. Experiences of the first 150 patients in Heidelberg. *Strahlenther Onkol.* 2008; 184: 8-14.
 32. Katz A, Kang J. Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study. *Radiat Oncol.* 2014; 9: 1.
 33. Yu JB, Efstathiou JA, Bekelman JE. Proton radiotherapy for prostate cancer: how did we get here, and where do we go from here? *Oncology (Williston Park).* 2013; 27: 1293-1294.
 34. Challapalli A, Jones E, Harvey C, Hellowell GO, Mangar SA. High dose rate prostate brachytherapy: an overview of the rationale, experience and emerging applications in the treatment of prostate cancer. *Br J Radiol.* 2012; 85 Spec No 1: S18-27.
 35. Aneja S, Yu JB. Comparative effectiveness research in radiation oncology: stereotactic radiosurgery, hypofractionation, and brachytherapy. *Semin Radiat Oncol.* 2014; 24: 35-42.
 36. Zaorsky NG, Harrison AS, Trabulsi EJ, Gomella LG, Showalter TN, Hurwitz MD, et al. Evolution of advanced technologies in prostate cancer radiotherapy. *Nat Rev Urol.* 2013; 10: 565-579.
 37. Mishra MV, Showalter TN. Pushing the limits of radiation therapy for prostate cancer: where do we go next? *Semin Oncol.* 2013; 40: 297-307.
 38. Sperduto PW, Wang M, Robins HI, Schell MC, Werner-Wasik M, Komaki R, et al. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. *Int J Radiat Oncol Biol Phys.* 2013; 85: 1312-1318.
 39. Ricchetti F, Barra S, Agostinelli S, Vagge S, Marcenaro M, and Corvo R, et al. Feasibility of helical tomotherapy for radical dose retreatment in pelvic area: a report of 4 cases. *Tumori.* 2011; 97: 492-497.

40. Nguyen PL, Chen RC, Clark JA, Cormack RA, Loffredo M, McMahon E, et al. Patient-reported quality of life after salvage brachytherapy for radio-recurrent prostate cancer: A prospective Phase II study. *Brachytherapy*. 2009; 8: 345-352.
41. Vavassori A, Jerezek-Fossa BA, Beltramo G, De Cicco L, Fariselli L, Bianchi LC, et al. Image-guided robotic radiosurgery as salvage therapy for locally recurrent prostate cancer after external beam irradiation: retrospective feasibility study on six cases. *Tumori*. 2010; 96: 71-75.
42. Jerezek-Fossa BA, Beltramo G, Fariselli L, Fodor C, Santoro L, Vavassori A, et al. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. *Int J Radiat Oncol Biol Phys*. 2012; 82: 889-897.
43. Dewas S, Bibault JE, Mirabel X, Nickers P, Castelain B, Lacommerie T, et al. Robotic image-guided reirradiation of lateral pelvic recurrences: preliminary results. *Radiat Oncol*. 2011; 6: 77.
44. Tharavichitkul E, Meungwong P, Chitapanarux T, Chakrabandhu S, Klunklin P, Onchan W, et al. The association of rectal equivalent dose in 2 Gy fractions (EQD2) to late rectal toxicity in locally advanced cervical cancer patients who were evaluated by rectosigmoidoscopy in Faculty of Medicine, Chiang Mai University. *Radiat Oncol J*. 2014; 32: 57-62.
45. Jeong S, Yoo EJ, Kim JY, Han CW, Kim KJ, and Kay CS. Re-irradiation of unresectable recurrent head and neck cancer: using Helical Tomotherapy as image-guided intensity-modulated radiotherapy. *Radiat Oncol J*. 2013; 31: 206-215.
46. Stuschke M, Kaiser A, Abu-Jawad J, Pottgen C, Levegrun S, and Farr J. Re-irradiation of recurrent head and neck carcinomas: comparison of robust intensity modulated proton therapy treatment plans with helical tomotherapy. *Radiat Oncol*. 2013; 8: 93.
47. Lin YW, Lin KH, Ho HW, Lin HM, Lin LC, Lee SP, et al. Treatment plan comparison between stereotactic body radiation therapy techniques for prostate cancer: Non-isocentric CyberKnife versus isocentric RapidArc. *Phys Med*. 2014.